Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Change in Receivables (2022 - 2025)

Historic Change in Receivables for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to -$54000.0.

  • Corvus Pharmaceuticals' Change in Receivables fell 25428.57% to -$54000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$38000.0, marking a year-over-year increase of 8967.39%. This contributed to the annual value of $49000.0 for FY2024, which is 10871.89% up from last year.
  • According to the latest figures from Q3 2025, Corvus Pharmaceuticals' Change in Receivables is -$54000.0, which was down 25428.57% from $7000.0 recorded in Q2 2025.
  • Corvus Pharmaceuticals' Change in Receivables' 5-year high stood at $130000.0 during Q3 2022, with a 5-year trough of -$429000.0 in Q2 2023.
  • In the last 4 years, Corvus Pharmaceuticals' Change in Receivables had a median value of $6000.0 in 2024 and averaged -$40333.3.
  • Its Change in Receivables has fluctuated over the past 5 years, first soared by 21818.18% in 2024, then crashed by 25428.57% in 2025.
  • Over the past 4 years, Corvus Pharmaceuticals' Change in Receivables (Quarter) stood at $85000.0 in 2022, then tumbled by 82.35% to $15000.0 in 2023, then plummeted by 66.67% to $5000.0 in 2024, then tumbled by 1180.0% to -$54000.0 in 2025.
  • Its Change in Receivables stands at -$54000.0 for Q3 2025, versus $7000.0 for Q2 2025 and $4000.0 for Q1 2025.